(Adnkronos) - In questo numero:
Gruppo Bracco inaugura Hexagon, il suo secondo stabilimento a Ginevra
Ricerca, all’università degli Studi di Milano il quinto Erc Synergy Grant
Diabete, gestione passa anche da corretta alimentazione e attività fisica. Utile il ruolo degli edulcoranti
Artrite psoriasica attiva: via libera di Aifa all’estensione di rimborsabilità di bimekizumab
E ancora
Luppi di Msd Italia, ‘innovazione fondamentale per crescita Paese’
Vaccini, ‘Abituati a proteggerti’ contro le malattie respiratorie infettive
È Raffaella Buzzetti la prima donna al vertice della Società italiana di diabetologia
Hackathon Synlab, vince il progetto Reviva
Gruppo Bracco inaugura Hexagon, il suo secondo stabilimento a Ginevra
Ricerca, all’università degli Studi di Milano il quinto Erc Synergy Grant
Diabete, gestione passa anche da corretta alimentazione e attività fisica. Utile il ruolo degli edulcoranti
Artrite psoriasica attiva: via libera di Aifa all’estensione di rimborsabilità di bimekizumab
E ancora
Luppi di Msd Italia, ‘innovazione fondamentale per crescita Paese’
Vaccini, ‘Abituati a proteggerti’ contro le malattie respiratorie infettive
È Raffaella Buzzetti la prima donna al vertice della Società italiana di diabetologia
Hackathon Synlab, vince il progetto Reviva
Category
🗞
NewsTranscript
00:00In this issue, Gruppo Bracco inaugurates Hexagon, its second plant in Ginevra.
00:17It is looking for the fifth IRC, Synergigrant, at the University of the South of Milan.
00:23Diabetes, management also goes from correct nutrition to physical activity, useful in the role of sweeteners.
00:31Active psoriasis arthritis, free route of Haifa to the extension of reimbursability of Bime Kizumab.
00:38And again.
00:40Lupi, of MSD Italia, fundamental innovation for country growth.
00:46Vaccines, get used to protect yourself against infectious respiratory diseases.
00:51And Raffaella Buzzetti, the first woman at the top of the Italian Diabetology Society.
00:57Acaton Syllab wins the REVIVA project.
01:06To respond to the high international demand of their drugs, Gruppo Bracco, leader in the diagnostic imaging,
01:12always in the forefront of scientific progress, thanks to its vocation for innovation,
01:16has built a second plant in Ginevra, located a few steps from the historic factory of 1997,
01:22and inaugurated on November 6.
01:24Once in full swing, Hexagon, this the name of the four-floor building,
01:28from the architectural architecture and built with the criteria of maximum sustainability,
01:33will triple the production and distribution of one of the leading products of the Bracco research,
01:38the innovative ultrasound contrast agent based on microbes.
01:42It was necessary to design, study and develop a contrast agent for ultrasound.
01:49And then we did it by taking contact with the Battelle Institute,
01:56always in Ginevra, where there was a group of very open researchers,
02:04who made themselves available to develop this concept.
02:11We have developed this category of echo contrasts, which are these bubbles.
02:20Today used for diagnostic in real time, the contrast agent based on microbes,
02:25of which Bracco is the world leader, will soon find new fields of application.
02:29At this site we have a very important commitment on the technology of microbes.
02:36Bracco is a world leader, not only with the products that are currently approved and used,
02:46but above all, as regards the effort of innovation,
02:51with the third generation of products that are now in clinical phase,
02:56and above all with the application of microbes in areas always linked to medicine,
03:03but not only to diagnostics.
03:05At the cutting of the inaugural ribbon, the Swiss ambassador was also present in Italy.
03:10Bracco now has a relationship with Switzerland for 40 years and we are very, very proud of it.
03:15It is a beautiful thing, also the fact that reality Bracco,
03:18who believe in us in our country, who come here,
03:21who also take advantage of this place that is Ginevra,
03:25where there is the highly qualified workforce, there is stability, etc.
03:30It is a great honor and it is underlining the importance of the bilateral relationship Italy-Switzerland.
03:36A strong applause for Bracco's commitment to innovation in the medical and scientific field
03:41also came from the Italian ambassador in Switzerland.
03:44An investment of 80 million francs,
03:49the creation of tens, hundreds of jobs to export in the whole world
03:54of cutting-edge products is an extraordinary contribution
03:58for the promotion of health and for the improvement of patient care.
04:08Revolutionize the field of therapy based on stem cells for neurodegenerative diseases,
04:14developing innovative and personalized cellular products
04:18able to meet the various therapeutic needs of patients.
04:22This is the goal of the 5th IRC Synergy Grant won by the University of Milan,
04:27a new international recognition for the work of state scientists,
04:31which this year was awarded to the research team of Senator Elena Cattaneo
04:36and a doctor of pharmacology at the State University of Milan.
04:39In this scenario, the scientific research of the State Frontier,
04:43with international success,
04:45was at the heart of the press conference held at the boardroom of the rectorate of the same university.
04:51We are particularly proud because it is one of the highest recognitions
04:56for research at the European and international level.
04:59These are projects that particularly reward the cohesion
05:03and collaboration of research groups at the international level,
05:07therefore the ability to make a team and to work on the same topic
05:12starting from different athens and different research groups.
05:16This is a recognition of great value,
05:19we are the only ones in 2024 in Milan
05:23and today we also take the opportunity to present the projects
05:27that are the winning results of the IRC Synergy Grant in recent years,
05:33always researchers from the State University of Milan,
05:36and to make a point about the advancement of these projects,
05:39all of them of great international importance.
05:43The Synergy Grants granted by the European Research Council
05:46are particular forms of grants
05:48dedicated to research projects of excellence
05:50that receive a total funding of about 10 million euros for six years.
05:55Since 2007, when the European Research Council was established,
05:59a thousand projects of Italian universities have been funded
06:02for a value of almost one billion euros.
06:05And what do they consist of?
06:07They are mainly about research groups
06:10with different skills and expertise
06:15and that synergize precisely to find innovative solutions
06:18in the research sector.
06:20So they are certainly a fundamental point
06:23for what concerns research and innovation at the European level.
06:27With the Custom Made project, Neuron for Cell Therapy
06:31in Parkinson's and Huntington's Disease,
06:33Elena Cattaneo's research team is thus awarded
06:36the 5th IRC Synergy Grant of the University of Milan.
06:40This is a project that we have been pursuing for two years.
06:44It is a European, competitive and prestigious funding
06:48that involves three other women, three scientists with me,
06:52another colleague from the University of Turin, Anna-Lisa Buffo,
06:56then Jenny Mneus from the University of Denmark
06:59and Malin Parmar from the University of Lund.
07:02Together, the four of us, we have set ourselves the goal
07:06of developing new strategies based on stem cells
07:12for the treatment of neurodegenerative diseases
07:17such as Parkinson's and Huntington's.
07:20The current clinical experimentation strategies
07:24require that for Parkinson's and Huntington's diseases
07:30we proceed with the transplant of the same cellular preparation.
07:34But we know that the disease manifests itself
07:37with different characteristics in different patients,
07:40so we need to produce stem cell preparations
07:44suitable for the different needs of the patient.
07:48This is the goal.
07:50We will have six years to achieve this goal.
07:53It will be a lot of research, it will be a great team effort
07:57and we really have to thank Europe,
08:00which gives us the motivation, the strength and the goal
08:05to overcome the boundaries to work together for the benefit of the citizens.
08:15About 6% of the population, that is 4 million Italians,
08:18lives with the most widespread form of diabetes, type 2 diabetes.
08:22It is estimated that globally there are over 530 million
08:26adults affected by diabetes,
08:28a number intended to increase to 640 million in 2030,
08:32according to the Italian Barometer Diabetes Report 2024.
08:37Faced with this negative trend,
08:39a fundamental practice for both prevention and management
08:42of this pathology is sport.
08:44Even if today in Italy more than 19.4 million people
08:49do not practice any.
08:51However, the benefits of physical activity for diabetic subjects are many
08:55and can be maximized by following a balanced diet.
08:59On the occasion of the World Diabetes Day,
09:02Unione Italiana Food, an edulcorating group,
09:04emphasizes the importance of promoting a correct diet
09:08among people who suffer from this pathology
09:11and intends to encourage a debate on the useful role of sweeteners
09:15in line with the opinion of experts.
09:17Sweeteners are substances that are used to sweeten foods
09:21without bringing calories.
09:23They are very important in the campaign against obesity
09:26because they allow us to reduce the overall caloric intake
09:30and obesity we know is one of the main factors in the risk of diabetes.
09:34In diabetics in particular, they help to prevent the increase
09:38of post-prandial glycemia, which instead occurs with the use of sugars.
09:41Glycemic control is therefore the standard word for those who live with diabetes
09:46and to do so, experts recommend the best practices
09:50able to combine a correct diet and healthy lifestyle.
09:53The correct diet goes from a planning of meals,
09:56not only in terms of choosing individual nutrients,
09:59but also in the timing of meal times,
10:03which must keep in mind the pre-race and the post-race.
10:07Let us remember that hydration is the pillar of the correction
10:11of deficiencies that can occur during physical activity,
10:14as well as the choice of individual nutrients.
10:17It is essential to measure glycemia before and after physical activity
10:22in subjects who begin to do this type of sport,
10:26as well as the advice that the doctor is always present
10:29in the management of these events.
10:32Therefore, nutrition as a pillar alongside physical activity
10:36in the choice of nutrients, in the timing and also, for example,
10:39in the use of sweeteners as a substitute for simple sugars
10:42to avoid glycemic outbursts during sports activity.
10:50It affects more than 100,000 people in Italy,
10:52with prevalence between 30 and 50 years of age and without gender differences,
10:56limiting mobility due to joint pain and swelling
10:59and impacting the quality of life.
11:01It is active psoriasis arthritis,
11:03a chronic and serious systemic inflammatory condition
11:06that affects both joints and skin.
11:09Thanks to AIFA's free road, the extension of the reimbursability
11:12of the monoclonal antibody B. mechizumab for this pathology,
11:15after having granted it in 2023 for moderate to severe plaque psoriasis,
11:19patients who suffer from active psoriasis arthritis
11:22will be able to take advantage of a new therapeutic option
11:25able to offer a high level of disease control
11:28in the results of skeletal and skin muscles.
11:30B. mechizumab is a monoclonal antibody
11:33that links two fundamental inflammatory factors for the development of the disease
11:38which are interleukin A17 and F.
11:41It has been approved also for psoriasis arthritis
11:45and therefore we can block the progression of psoriasis to arthritis
11:53but also the pain and the arthritis itself
11:58using a single drug that blocks two inflammatory factors.
12:02To confirm the effectiveness, tolerability and safety of the monoclonal antibody
12:06in the treatment of active psoriasis arthritis,
12:08the results at 52 weeks of the open B. complete B. vital extension study
12:13based on the 16-week data of the B. complete study
12:17and on those at 52 of the B. optimal study.
12:20The long-term data show that more than 6 patients out of 10 treated
12:24continuously with B. mechizumab
12:26have obtained a complete skin clearance
12:29and almost 1 in 2 had a minimal disease activity at the 52nd week.
12:34From a rheumatological point of view,
12:36the most interesting result is linked to the number of patients
12:40who achieve a result called MDA,
12:43that is Minimal Disease Activity.
12:45This MDA, which is a situation very close to complete remission,
12:49is achieved in a very high percentage of patients
12:52and therefore this gives us great hope in real life
12:55to achieve the same result in the patients we see in the clinic.
12:58The introduction of this biological therapy
13:00in the range of treatment options available to clinics
13:03gives patients the hope of a better quality of life.
13:07UCB Pharma has been researching in various fields for almost 100 years,
13:12but lately it has concentrated its research in immunology and neurology.
13:17Last year it invested almost 30% of its turnover,
13:21which is 5.3 billion, in research and development.
13:25And we do it with a precision research
13:27based on antibodies and small molecules.
13:30It is a commitment that has certainly already yielded great results,
13:34this one that we are launching today is a very important indication,
13:38but it will go on and, in short,
13:41new answers should really arrive for the needs of patients
13:44who are still not satisfied.
13:51In the pharmaceutical field, innovation remains a central theme.
13:54From innovation comes the possibility of economic and social growth
13:58of an entire country.
14:00In addition, of course, to continue to offer new solutions for patients.
14:04This was also discussed at the 19th Meridiano Sanità Forum
14:08Health for All Policies,
14:10towards a new strategic vision of the health system
14:13for the growth of the country, which is based in Rome.
14:16Innovation will be central to guarantee not only sustainability
14:21in the health system, but also a real advancement
14:25and a possibility of economic and social growth
14:28for our country.
14:30And if we want to expand also throughout Europe,
14:33which must become more and more attractive not only to innovation,
14:37but compared to all those investments
14:40that innovation brings with it.
14:42A country, a continent without innovation,
14:45is a country, a continent that has no future.
14:48A country in which politics can do its part,
14:50simplifying the processes and promoting the activities
14:53of those who are committed to innovation.
14:55A goal that has been really taken into account
14:58is the new balance sheet law,
15:00which is hoped to be revised in any case
15:03in order to become really encouraging
15:06compared to those who want to increase innovation in this country.
15:10And so I hope not only that we can also increase more,
15:14also for 2025, the national health fund.
15:17I hope that we can increase the percentage
15:20within the national health fund,
15:23in general for pharmaceutical consumption,
15:26but above all that percentage
15:29for direct purchases,
15:32because it is above all there that the great innovation happens.
15:36And then, especially for patients,
15:39I hope that that great step forward can be revised,
15:42which is the revision of the Fund for Innovative Pharmaceuticals,
15:46which is urgent compared to all the innovation
15:49that can really be carried out in our country,
15:52which has also been expanded to conditioned innovativeness
15:55and also to the so-called reserve antibiotics,
15:58which, however, as far as conditioned innovations are concerned,
16:02is conditioned and therefore feasible
16:05only within the first six years
16:08of obtaining the first label of innovation
16:11by the drug itself.
16:14This is a limit, frankly, from a point of view
16:17not only scientific, unacceptable,
16:20because there must be no brakes of any kind,
16:23especially from a bureaucratic point of view,
16:26to innovation, but above all for patients,
16:29because every new indication,
16:32every possibility of innovativeness
16:35linked to a molecule or more molecules,
16:38can really make the difference
16:41between life and death.
16:51There are about 2.5 million deaths globally,
16:54according to the WHO,
16:57caused by respiratory infections.
17:00In a note disseminated by the Ministry of Health
17:03on prevention and control of influenza,
17:06in Italy, influenza and pneumonia associated with it
17:09are classified among the first ten main causes of death.
17:12Despite the data, however,
17:15Italy ranks between 16th and 17th
17:18in 28 European countries for vaccine coverage
17:21in the different age groups,
17:24according to the ECDC report.
17:27This was mentioned in an event organized in Rome by Pfizer,
17:30which brought together a task force of experts
17:33on the most effective prevention strategies
17:36against seasonal respiratory infections.
17:39Many viruses and many bacteria can cause respiratory infections,
17:42but there are some of these that manifest themselves
17:45in a more serious way,
17:48and among the viruses, certainly the influenza viruses,
17:51obviously COVID, but the respiratory virus
17:54is a virus that actually often
17:57affects adults,
18:00and just like influenza and COVID,
18:03it can cause extremely serious manifestations
18:06that can lead to hospitalization,
18:09intensive care,
18:12and even in a small number of cases,
18:15in Italy it is estimated that there are at least 2,000 deaths per year
18:18due to the seasonal respiratory virus.
18:21During the meeting, Pfizer launched the campaign
18:24Get used to protect yourself,
18:27which was authorized by the Ministry of Health
18:30in support of an integrated approach to prevention,
18:33with particular attention to the most at-risk categories,
18:36such as the elderly and people with immune disabilities.
18:39We know the costs in terms of human lives.
18:42Influenza causes about 8,000 deaths per year,
18:45as well as COVID and RSV,
18:48perhaps a few lives less,
18:51but certainly a fairly high number of hospitalizations.
18:54The challenge is to be able to cover
18:57the elderly and vulnerable population
19:00for all the infectious and respiratory pathologies
19:03that can have a vaccine prevention.
19:06During the meeting organized in Rome,
19:09the key role of general medicine and pharmacies
19:12has been emphasized in promoting prevention
19:15to raise awareness of the population
19:18and facilitate access to preventive measures.
19:21We really need a return of confidence
19:24towards vaccination,
19:27which is and remains a fundamental element
19:30to ensure that the pathologies
19:33are as less impactful as possible.
19:40Raffaella Buzzetti is the first woman
19:43at the top of the Italian Diabetes Society,
19:46a name that has been around since this year,
19:49President-elect since 2022,
19:52Professor in Endocrinology
19:55of the Department of Experimental Medicine
19:58of the Faculty of Medicine and Dentistry
20:01of the University of Sapienza in Rome.
20:04She took on all the effects of this position
20:07on the occasion of the 30th Congress
20:10of the Italian Diabetes Society.
20:13Among the goals set by SID with its election,
20:16the answer that came to mind was now,
20:19in the sense that we were perhaps
20:22one of the last scientific societies
20:25in which there had not yet been a female president.
20:28I hope it is the beginning
20:31and for many other young colleagues
20:34who have all the characteristics
20:37that I hope in the future
20:40they can follow my first female presidency.
20:43In order to give a touch of femininity,
20:46if I may call it that,
20:49we will work hard in the study of diabetes
20:52in the male and female gender,
20:55in the differences.
20:58There is a lot of attention in making a gender medicine
21:01and I think it is a really right thing.
21:04Even in diabetes and metabolic diseases
21:07there are many differences,
21:10both in the prevalence of type 1 and type 2 diabetes
21:13and in the risk of complications.
21:16This is due to the different chromosomes
21:19and also to the differences in gender and also environmental.
21:22I would like to give a boost to research in this area
21:25and also to the deepening of the themes
21:28in this direction,
21:31because clinical studies are carried out
21:34mainly in 60-70% of cases in men.
21:38This is worldwide and international,
21:41not only in Italy,
21:44and I think it is appropriate in the future
21:47to have a change and to deepen these themes.
21:50Beyond this, I hope to be able to
21:53take advantage of the ability
21:56of many female colleagues in the board,
21:59I must say that there have always been
22:02and there will be in the next board,
22:05to be able to emphasize and enhance
22:08the characteristics of female diabetologists
22:11compared to those of men.
22:14And how do you feel about being able to perform all the various tasks of a president of SID?
22:17For me it is a great joy,
22:20in the sense that, let's say,
22:23to become president I certainly feel it as a responsibility,
22:26but also as a great challenge,
22:29a great stimulus to try to do
22:32the best in the wave of what has been done so far.
22:38I have always believed in the Italian Society of Diabetology,
22:41in SID,
22:44and I hope that in the next two years
22:47SID believes in me,
22:50in my enthusiasm and in pursuing,
22:53both from the point of view of training young people,
22:56I think it is one of the fundamental goals,
22:59that in the development of studies,
23:02we have the SID Research Center,
23:05which has produced scientific works and studies of excellence,
23:08which continue in this direction,
23:11in stimulating the implementation of technologies
23:14in diabetology,
23:17which have undergone a great improvement
23:20in recent years,
23:23and also in trying more and more to interlocute
23:26with our administrators,
23:29precisely for the improvement of the assistance,
23:32therefore of the quality of life of people with diabetes,
23:35in the context of a collaboration with other scientific societies,
23:38MDs, others,
23:41and certainly patient associations.
23:44Based on your experience, how would you define SID?
23:47Home, passion.
23:50These are certainly
23:53the things that come to mind.
23:56It is really a great fortune for us
23:59to have had the Italian Society of Diabetology,
24:02which has constantly accompanied us over the years,
24:05almost taking us by the hand as young people,
24:08as neo-specialists, perhaps even before,
24:11and stimulating us, let's say,
24:14to be able to publish works internationally,
24:17and certainly the presence of others,
24:20of colleagues,
24:23has been a great stimulus for all of us.
24:30The third edition of the ACATON
24:33of the SYNLAB Italia group was concluded
24:36with the awarding of the REVIVA project.
24:39The competition, which also this year
24:42at the MIND in Milan saw young university students
24:45challenging themselves in the creation of innovative solutions
24:48for cybersecurity and data science
24:51to improve the quality of life of patients.
24:54The ACATON was organized in the context of a program
24:57developed by the European Institute of Innovation and Technology,
25:00in collaboration with Cariplo Factory,
25:03Federated Innovation MIND
25:06and the University of the Studies of Naples Federico II.
25:09This year we had a lot of applications,
25:12unfortunately we had to make some selections,
25:15but the ACATON is a great opportunity for SYNLAB
25:18to get in touch with talents
25:21and to see these young people working
25:24in the creation of new things.
25:27Our sector is very important,
25:30so it's great to be with them and see the energy
25:33that these young people develop.
25:36Often there is a climate of discomfort
25:39compared to the new generation.
25:42This is a demonstration
25:45of how the new generations are full of energy
25:48and when they are given the opportunity
25:51they put it into action and show us
25:54what they can do, that they are real talents.
25:57I think this is one of the commitments
26:00that companies like ours, big companies,
26:03must take and give the opportunity to the talents to express themselves,
26:06because they are our future, but also our present.
26:09Among the illustrious guests,
26:12also the entrepreneur and scientist Massimo Temporelli,
26:15who gave an important speech to the students.
26:18There were over 100 university students from all over Italy
26:21who were then selected to participate in the ACATON.
26:24Today we had the opportunity to present REVIVA,
26:27which is our project that we have developed here at the ACATON of SYNLAB.
26:30REVIVA is an application that aims
26:33to allow doctors and patients to continue
26:36the rehabilitation process after having undergone an ICTUS.
26:39How does it do it?
26:42It does it using AI models that can give direct advice
26:45to the exercises that the patients do directly at home.
26:48In addition, REVIVA also aims
26:51not only to cover
26:54physical rehabilitation,
26:57but also in terms of language,
27:00and therefore it is able to give feedback
27:03regarding the pronunciation of words
27:06and advice to improve this aspect of rehabilitation.
27:09The idea for this application
27:12came to us after discovering that
27:15in Italy, unfortunately, many infrastructures are missing
27:18both in terms of buildings where rehabilitation is carried out,
27:21but also medical personnel available to offer rehabilitation services,
27:24but not only, above all,
27:27financial aid is missing to continue rehabilitation
27:30within hospitals, which is a cost
27:33that the regions must support and is very high.
27:36For this reason, with REVIVA it is possible
27:39to continue this process of rehabilitation at home
27:42and in this way also directly hospitals
27:45and the health system could take advantage of it.
27:52This was our latest news.
27:55To contact us, you can write to salute-adnchronos.com
27:58Thank you for following us and see you next time.